1. Home
  2. ZSTK vs SER Comparison

ZSTK vs SER Comparison

Compare ZSTK & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ZSTK

ZeroStack Corp. Common Stock

N/A

Current Price

$5.18

Market Cap

20.0M

Sector

Health Care

ML Signal

N/A

Logo Serina Therapeutics Inc.

SER

Serina Therapeutics Inc.

HOLD

Current Price

$1.98

Market Cap

19.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZSTK
SER
Founded
2019
2017
Country
Canada
United States
Employees
76
13
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.0M
19.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ZSTK
SER
Price
$5.18
$1.98
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$15.00
AVG Volume (30 Days)
13.6K
7.6M
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$15.73
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.77
$1.22
52 Week High
$11.00
$7.92

Technical Indicators

Market Signals
Indicator
ZSTK
SER
Relative Strength Index (RSI) 34.01 48.03
Support Level N/A $1.55
Resistance Level $9.45 $3.16
Average True Range (ATR) 0.88 0.35
MACD -0.21 -0.03
Stochastic Oscillator 8.70 14.60

Price Performance

Historical Comparison
ZSTK
SER

About ZSTK ZeroStack Corp. Common Stock

ZeroStack Corp is an AI focused asset management company. The company also operates a world-wide pharmaceutical distribution business through its wholly owned subsidiary. ZeroStack is focused on providing exposure to decentralized AI through a concentrated digital asset approach structured to generate yield and fee-based income from staking validators, compute power technology companies, and complementary businesses within the ecosystem and across the wider AI landscape.

About SER Serina Therapeutics Inc.

Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.

Share on Social Networks: